M6A Demethylase FTO Targets Pcsk9 to Inhibit Vascular Calcification in Chronic Kidney Disease
Arteriosclerosis, thrombosis, and vascular biology · Xie et al.
doi.org/10.1161/atvbaha.126.324532
#RNAsky #RNAmods
Arteriosclerosis, thrombosis, and vascular biology · Xie et al.
doi.org/10.1161/atvbaha.126.324532
#RNAsky #RNAmods
M6A Demethylase FTO Targets Pcsk9 to Inhibit Vascular Calcification in Chronic Kidney Disease
Arteriosclerosis, thrombosis, and vascular biology · Xie Y, Zhao H, Lan L, Liu R, Zheng M, Zhong G, Yuan L, Li K, Macrae VE, He S, Hao Y, Yuan L, Chen G, Zhu D, Yu H.
doi.org
October 2, 2026 at 9:06 PM
M6A Demethylase FTO Targets Pcsk9 to Inhibit Vascular Calcification in Chronic Kidney Disease
Arteriosclerosis, thrombosis, and vascular biology · Xie et al.
doi.org/10.1161/atvbaha.126.324532
#RNAsky #RNAmods
Arteriosclerosis, thrombosis, and vascular biology · Xie et al.
doi.org/10.1161/atvbaha.126.324532
#RNAsky #RNAmods
Today, siRNA drugs are largely used to treat liver diseases, partly because that’s the easiest starting point.
And they are extremely effective at it. One example is for cholesterol: siRNA drugs reduce PCSK9 levels by around 70%, reducing cholesterol levels by 50-60%, beyond the effect of statins.
And they are extremely effective at it. One example is for cholesterol: siRNA drugs reduce PCSK9 levels by around 70%, reducing cholesterol levels by 50-60%, beyond the effect of statins.
October 2, 2026 at 1:45 PM
Today, siRNA drugs are largely used to treat liver diseases, partly because that’s the easiest starting point.
And they are extremely effective at it. One example is for cholesterol: siRNA drugs reduce PCSK9 levels by around 70%, reducing cholesterol levels by 50-60%, beyond the effect of statins.
And they are extremely effective at it. One example is for cholesterol: siRNA drugs reduce PCSK9 levels by around 70%, reducing cholesterol levels by 50-60%, beyond the effect of statins.
- Cardiovascular diseases, silencing proteins like PCSK9 that raise cholesterol
- Cancers, by silencing proteins that help tumour cells grow, survive, metabolize, metastasize, or resist treatment
- and more!
- Cancers, by silencing proteins that help tumour cells grow, survive, metabolize, metastasize, or resist treatment
- and more!
October 2, 2026 at 1:45 PM
- Cardiovascular diseases, silencing proteins like PCSK9 that raise cholesterol
- Cancers, by silencing proteins that help tumour cells grow, survive, metabolize, metastasize, or resist treatment
- and more!
- Cancers, by silencing proteins that help tumour cells grow, survive, metabolize, metastasize, or resist treatment
- and more!
Oral macrocyclic PCSK9 inhibitor secures FDA approval www.nature.com/articles/d41...
Oral macrocyclic PCSK9 inhibitor secures FDA approval
Discover the world’s best science and medicine | Nature.com
www.nature.com
September 30, 2026 at 10:47 PM
Oral macrocyclic PCSK9 inhibitor secures FDA approval www.nature.com/articles/d41...
The Curbsiders Internal Medicine Podcast
#540 Hotcakes: Varenicline by mail for smoking cessation, anticoagulation for intermediate risk AF, CAC score plus PREVENT, blood testing for CRC, oral PCSK9 inhibitors, and more
The Curbsiders Internal Medicine Podcast · Episode
open.spotify.com
September 30, 2026 at 12:27 PM
The Curbsiders Internal Medicine Podcast
Also read the original TimeCapsule article:
A quarter-century of progress: innovations in lipid medicine that transformed cardiovascular prevention thelancet.com/journals/lan...
#LDL #cholesterol #ASCVD #statins #PCSK9 inhibitors
#MedSky #EndoSky #CardioSky
A quarter-century of progress: innovations in lipid medicine that transformed cardiovascular prevention thelancet.com/journals/lan...
#LDL #cholesterol #ASCVD #statins #PCSK9 inhibitors
#MedSky #EndoSky #CardioSky
A quarter-century of progress: innovations in lipid medicine that transformed cardiovascular prevention
This TimeCapsule reviews the major transformations in lipid metabolism and cardiovascular
disease prevention during the first quarter of the 21st century and their impact on
clinical practice. From la...
thelancet.com
September 29, 2026 at 9:45 AM
Also read the original TimeCapsule article:
A quarter-century of progress: innovations in lipid medicine that transformed cardiovascular prevention thelancet.com/journals/lan...
#LDL #cholesterol #ASCVD #statins #PCSK9 inhibitors
#MedSky #EndoSky #CardioSky
A quarter-century of progress: innovations in lipid medicine that transformed cardiovascular prevention thelancet.com/journals/lan...
#LDL #cholesterol #ASCVD #statins #PCSK9 inhibitors
#MedSky #EndoSky #CardioSky
25 Years of Lipid Medicine youtube.com/watch?v=atCH...
#LDL #cholesterol #ASCVD
#statins #PCSK9 inhibitors
#MedSky #EndoSky #CardioSky
#LDL #cholesterol #ASCVD
#statins #PCSK9 inhibitors
#MedSky #EndoSky #CardioSky
25 Years of Lipid Medicine
YouTube video by The Lancet
youtube.com
September 29, 2026 at 9:45 AM
25 Years of Lipid Medicine youtube.com/watch?v=atCH...
#LDL #cholesterol #ASCVD
#statins #PCSK9 inhibitors
#MedSky #EndoSky #CardioSky
#LDL #cholesterol #ASCVD
#statins #PCSK9 inhibitors
#MedSky #EndoSky #CardioSky
Product Citation💡A study out of the Rush University Medical Center used StressMarq's ENaC antibodies (SPC-403, SPC-404, & SPC-405) to investigate the role of CCD-secreted PCSK9 in MCD-associated hypercholesterolemia.
Products📘https://bit.ly/4uXyQf2
Paper📖https://bit.ly/4nJGXcS
Products📘https://bit.ly/4uXyQf2
Paper📖https://bit.ly/4nJGXcS
September 28, 2026 at 6:49 PM
Product Citation💡A study out of the Rush University Medical Center used StressMarq's ENaC antibodies (SPC-403, SPC-404, & SPC-405) to investigate the role of CCD-secreted PCSK9 in MCD-associated hypercholesterolemia.
Products📘https://bit.ly/4uXyQf2
Paper📖https://bit.ly/4nJGXcS
Products📘https://bit.ly/4uXyQf2
Paper📖https://bit.ly/4nJGXcS
▲ NSE:SUNPHARMA Sun Pharma: Exclusive licensing deal for PCSK9 inhibitor (EU-approved Sep 21) targeting a $3.7B market (ex-US/China) growing at 38% CAGR. Strengthens innovative portfolio with a blockbuster drug, despite confidential financials. [BULLISH]
September 28, 2026 at 5:03 AM
▲ NSE:SUNPHARMA Sun Pharma: Exclusive licensing deal for PCSK9 inhibitor (EU-approved Sep 21) targeting a $3.7B market (ex-US/China) growing at 38% CAGR. Strengthens innovative portfolio with a blockbuster drug, despite confidential financials. [BULLISH]
From Pan-Cancer Transcriptomics to Trial Alignment: Systematic Prioritization of PCSK9-Targeted Oncology Indications #SingleCell 🧪🧬🖥️
https://www.researchsquare.com/article/rs-10699027/latest
https://www.researchsquare.com/article/rs-10699027/latest
September 28, 2026 at 1:00 AM
From Pan-Cancer Transcriptomics to Trial Alignment: Systematic Prioritization of PCSK9-Targeted Oncology Indications #SingleCell 🧪🧬🖥️
https://www.researchsquare.com/article/rs-10699027/latest
https://www.researchsquare.com/article/rs-10699027/latest
PotM#70
„PCSK9-Hemmung ohne Spritze?“ 💊
Enlicitide senkt LDL-C in der Phase-3-Studie CORALReef Lipids um rund 56 % gegenüber Placebo. Könnte die orale Therapie die nächste große Erweiterung der Lipidsenkung werden?
👉 Jetzt im neuen YD Paper of the Month nachlesen.
🖇️: www.pdffiller.com/s/YMdEy5bN
„PCSK9-Hemmung ohne Spritze?“ 💊
Enlicitide senkt LDL-C in der Phase-3-Studie CORALReef Lipids um rund 56 % gegenüber Placebo. Könnte die orale Therapie die nächste große Erweiterung der Lipidsenkung werden?
👉 Jetzt im neuen YD Paper of the Month nachlesen.
🖇️: www.pdffiller.com/s/YMdEy5bN
Outdated Browsers
www.pdffiller.com
September 27, 2026 at 8:39 AM
PotM#70
„PCSK9-Hemmung ohne Spritze?“ 💊
Enlicitide senkt LDL-C in der Phase-3-Studie CORALReef Lipids um rund 56 % gegenüber Placebo. Könnte die orale Therapie die nächste große Erweiterung der Lipidsenkung werden?
👉 Jetzt im neuen YD Paper of the Month nachlesen.
🖇️: www.pdffiller.com/s/YMdEy5bN
„PCSK9-Hemmung ohne Spritze?“ 💊
Enlicitide senkt LDL-C in der Phase-3-Studie CORALReef Lipids um rund 56 % gegenüber Placebo. Könnte die orale Therapie die nächste große Erweiterung der Lipidsenkung werden?
👉 Jetzt im neuen YD Paper of the Month nachlesen.
🖇️: www.pdffiller.com/s/YMdEy5bN
FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol
zurl.co/RJ87R
zurl.co/RJ87R
FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol
The US Food and Drug Administration (FDA) approved the first oral protein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to reduce low-density lipoprotein (LDL) cholesterol. PCSK9 inhibitors have previously been available only as injectable therapies.
jamanetwork.com
September 24, 2026 at 9:00 PM
FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol
zurl.co/RJ87R
zurl.co/RJ87R
콜레스테롤 약 비교 핵심 5가지 👇
1. 스타틴은 생성을 겨냥
2. PCSK9 억제제는 제거를 겨냥
3. 수도꼭지 vs 배수구
4. 대체가 아니라 함께 쓰는 관계
5. 목표 수치는 사람마다 다르다
1. 스타틴은 생성을 겨냥
2. PCSK9 억제제는 제거를 겨냥
3. 수도꼭지 vs 배수구
4. 대체가 아니라 함께 쓰는 관계
5. 목표 수치는 사람마다 다르다
September 24, 2026 at 12:00 PM
콜레스테롤 약 비교 핵심 5가지 👇
1. 스타틴은 생성을 겨냥
2. PCSK9 억제제는 제거를 겨냥
3. 수도꼭지 vs 배수구
4. 대체가 아니라 함께 쓰는 관계
5. 목표 수치는 사람마다 다르다
1. 스타틴은 생성을 겨냥
2. PCSK9 억제제는 제거를 겨냥
3. 수도꼭지 vs 배수구
4. 대체가 아니라 함께 쓰는 관계
5. 목표 수치는 사람마다 다르다
Sustained epigenetic silencing in monkeys is made more efficient with optimized regulators go.nature.com/46uDMyK
rdcu.be/LRyz3xvXnWxa
rdcu.be/LRyz3xvXnWxa
Design of optimized epigenetic regulators for durable gene silencing with application to PCSK9 in nonhuman primates - Nature Biotechnology
Sustained epigenetic silencing in monkeys is made more efficient with optimized regulators.
go.nature.com
September 24, 2026 at 3:18 AM
Sustained epigenetic silencing in monkeys is made more efficient with optimized regulators go.nature.com/46uDMyK
rdcu.be/LRyz3xvXnWxa
rdcu.be/LRyz3xvXnWxa
September 23, 2026 at 12:00 PM
립펜드라 핵심 5가지 👇
1. 성분명 엔리시타이드
2. 2026년 7월 FDA 승인
3. 최초의 경구용 PCSK9 억제제
4. PCSK9은 LDL 수용체를 분해하는 단백질
5. 국내 허가는 2026년 9월 기준 확인 안 됨
1. 성분명 엔리시타이드
2. 2026년 7월 FDA 승인
3. 최초의 경구용 PCSK9 억제제
4. PCSK9은 LDL 수용체를 분해하는 단백질
5. 국내 허가는 2026년 9월 기준 확인 안 됨
September 23, 2026 at 12:00 PM
립펜드라 핵심 5가지 👇
1. 성분명 엔리시타이드
2. 2026년 7월 FDA 승인
3. 최초의 경구용 PCSK9 억제제
4. PCSK9은 LDL 수용체를 분해하는 단백질
5. 국내 허가는 2026년 9월 기준 확인 안 됨
1. 성분명 엔리시타이드
2. 2026년 7월 FDA 승인
3. 최초의 경구용 PCSK9 억제제
4. PCSK9은 LDL 수용체를 분해하는 단백질
5. 국내 허가는 2026년 9월 기준 확인 안 됨
In this case-based CME activity, Michael J. Blaha, MD, MPH, explores the evolving landscape of LDL-C management, including the current role of PCSK9 inhibitors and how new injectable and oral formulations may influence future care.
Review the case: www.youtube.com/watch?v=dMaG...
Review the case: www.youtube.com/watch?v=dMaG...
September 22, 2026 at 3:18 PM
In this case-based CME activity, Michael J. Blaha, MD, MPH, explores the evolving landscape of LDL-C management, including the current role of PCSK9 inhibitors and how new injectable and oral formulations may influence future care.
Review the case: www.youtube.com/watch?v=dMaG...
Review the case: www.youtube.com/watch?v=dMaG...
Evolocumab and Cardiovascular Events in Patients With Diabetes Without Known Significant Atherosclerosis
zurl.co/OrArZ
zurl.co/OrArZ
Evolocumab and Cardiovascular Events in Patients With Diabetes Without Known Significant Atherosclerosis
To the Editor To me, the principal unanswered question raised by the Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke (VESALIUS-CV) trial is whether that trial supports use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition...
jamanetwork.com
September 21, 2026 at 4:04 PM
Evolocumab and Cardiovascular Events in Patients With Diabetes Without Known Significant Atherosclerosis
zurl.co/OrArZ
zurl.co/OrArZ
Just out: Combining mRNA display and photo-crosslinking to discover high-affinity photo-reactive peptide probes for PCSK9
Combining mRNA display and photo-crosslinking to discover high-affinity photo-reactive peptide probes for PCSK9
Communications Chemistry, Published online: 19 September 2026; doi:10.1038/s42004-026-02204-2Photo-crosslinking is a powerful technique for probing complex biological systems, yet developing high-affinity peptides that efficiently crosslink with target proteins often demands extensive optimisation. Here, the authors introduce a single-round mRNA-based protocol that efficiently converts hit peptides into high-affinity photo-crosslinking variants, facilitating streamlined development of peptide probes for tracking protein interactions, exemplified by PCSK9 internalization.
dlvr.it
September 19, 2026 at 6:47 PM
Just out: Combining mRNA display and photo-crosslinking to discover high-affinity photo-reactive peptide probes for PCSK9
What I find fascinating as hell is that by the time we discovered that octopi edit over 13,000 RNA sites to adjust to the cold, human RNA drugs like Spinraza & Leqvio, a drug that targets PCSK9, similar to my Repatha comparison elsewhere had already been invented, approved, & injected into patients.
September 19, 2026 at 6:29 PM
What I find fascinating as hell is that by the time we discovered that octopi edit over 13,000 RNA sites to adjust to the cold, human RNA drugs like Spinraza & Leqvio, a drug that targets PCSK9, similar to my Repatha comparison elsewhere had already been invented, approved, & injected into patients.
PCSK9 proteins are kamikaze Shahed drones tracking the SAM sites' electronic signatures to blow them to hell.
Iran gains air superiority, and plaque blockades choke off the Strait of Hormuz.
Iran gains air superiority, and plaque blockades choke off the Strait of Hormuz.
September 19, 2026 at 5:52 PM
PCSK9 proteins are kamikaze Shahed drones tracking the SAM sites' electronic signatures to blow them to hell.
Iran gains air superiority, and plaque blockades choke off the Strait of Hormuz.
Iran gains air superiority, and plaque blockades choke off the Strait of Hormuz.
The PCSK9-inhibitor angle is wild — using a lipid-clearing mechanism to drag PFAS out as a kind of molecular hitchhiker. If it generalizes, we might have been sitting on a detox pathway without knowing it.
September 19, 2026 at 5:34 PM
The PCSK9-inhibitor angle is wild — using a lipid-clearing mechanism to drag PFAS out as a kind of molecular hitchhiker. If it generalizes, we might have been sitting on a detox pathway without knowing it.
25 Years of #Lipid Medicine
youtube.com/watch?v=atCH...
#LDL #cholesterol #ASCVD #statins #PCSK9 inhibitors #ezetimibe #RNA-based drugs #gene editing
youtube.com/watch?v=atCH...
#LDL #cholesterol #ASCVD #statins #PCSK9 inhibitors #ezetimibe #RNA-based drugs #gene editing
25 Years of Lipid Medicine
YouTube video by The Lancet
youtube.com
September 17, 2026 at 7:46 PM
25 Years of #Lipid Medicine
youtube.com/watch?v=atCH...
#LDL #cholesterol #ASCVD #statins #PCSK9 inhibitors #ezetimibe #RNA-based drugs #gene editing
youtube.com/watch?v=atCH...
#LDL #cholesterol #ASCVD #statins #PCSK9 inhibitors #ezetimibe #RNA-based drugs #gene editing
The authors included RRIDs in their in Biology Direct paper! We value the author's support of reproducibility. #OpenResearch #methodsmatter #OpenScience
PCSK9 inhibitors do not increase cognitive risk
Read the full paper: PCSK9 inhibitors do not increase cognitive risk
doi.org
September 16, 2026 at 7:39 PM
The authors included RRIDs in their in Biology Direct paper! We value the author's support of reproducibility. #OpenResearch #methodsmatter #OpenScience
元論文→ Reference: Jerabek S, Jung C, Kappy M, et al. Highly efficient base editing at PCSK9 and normal human embryo development. Nature. 2026. doi: 10.1038/s41586-026-11118-x
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Highly efficient base editing at PCSK9 and normal human embryo development - Nature
Nature - Highly efficient base editing at PCSK9 and normal human embryo development
www.nature.com
September 15, 2026 at 11:07 PM
元論文→ Reference: Jerabek S, Jung C, Kappy M, et al. Highly efficient base editing at PCSK9 and normal human embryo development. Nature. 2026. doi: 10.1038/s41586-026-11118-x
www.nature.com/articles/s41...
www.nature.com/articles/s41...